Synonym
Cyclazocine; NIH7981; NIH-7981; NIH 7981
IUPAC/Chemical Name
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-(cyclopropylmethyl)-6,11-dimethyl-
InChi Key
YQYVFVRQLZMJKJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3
SMILES Code
OC1=CC=C2C(C3(C)CCN(CC4CC4)C(C3C)C2)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
271.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Archer S, Glick SD, Bidlack JM. Cyclazocine revisited. Neurochem Res. 1996 Nov;21(11):1369-73. doi: 10.1007/BF02532378. PMID: 8947927.
2: Albertson NF. Cyclazocine and congeners. Adv Biochem Psychopharmacol. 1973;8(0):63-79. PMID: 4604288.
3: Preston KL, Umbricht A, Schroeder JR, Abreu ME, Epstein DH, Pickworth WB. Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behav Pharmacol. 2004 Mar;15(2):91-102. doi: 10.1097/00008877-200403000-00001. PMID: 15096909.
4: Maeda M, Tsuji A. Radioimmunoassay of cyclazocine and stereospecificity of antibody. J Pharmacobiodyn. 1981 Mar;4(3):167-74. doi: 10.1248/bpb1978.4.167. PMID: 7252767.
5: Glick SD, Visker KE, Maisonneuve IM. Effects of cyclazocine on cocaine self- administration in rats. Eur J Pharmacol. 1998 Sep 11;357(1):9-14. doi: 10.1016/s0014-2999(98)00548-2. PMID: 9788768.
6: Peterson JE, Barnick CT, Benziger D, Kullberg MP, Brown R, O'Melia P, Clemans S, Edelson J. Analysis of cyclazocine in plasma. J Pharm Sci. 1979 Nov;68(11):1447-50. doi: 10.1002/jps.2600681130. PMID: 512897.
7: Kim M, Pang K, Freedman R, Palmer M. Electrophysiological effects of cyclazocine on rat cerebellar Purkinje neurons: comparison with phencyclidine. Alcohol Drug Res. 1985-1986;6(1):23-36. PMID: 4074470.
8: Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther. 1986 Sep;238(3):960-8. PMID: 3018228.
9: Küçukhüseyin C. Cardiovascular effects of intravenous pentazocine and cyclazocine in conscious, curarized-conscious, and anesthetized dogs. J Basic Clin Physiol Pharmacol. 2003;14(3):235-55. doi: 10.1515/jbcpp.2003.14.3.235. PMID: 14964736.
10: Drew WG, Chamblin M, Miller LL. Comparison of the effects of cyclazocine and imipramine on the circadian sleep-waking cycle of the cat. Pharmacology. 1971;6(6):339-52. doi: 10.1159/000136262. PMID: 4338399.
